Amyris (AMRS) Reports Q4 Loss of $0.76
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amyris Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Announces Signing of $300 Million Definitive Cannabinoid Agreement
March 18, 2019 4:28 PM EDTEMERYVILLE, Calif., March 18, 2019 (GLOBE NEWSWIRE) --
Q4 2018 GAAP revenue of $19.4 million, compared with GAAP revenue of $80.6 million (reflected $57.3 million during period for agreement with DSM) for Q4 2017. Fourth-quarter revenue of $19.4 million compared with the same period in 2017 of $17.7 million when adjusted for the loss making product sales on contracts assigned to DSM and any one-time revenue. Signed $300 million definitive cannabinoid agreement with LAVVAN, Inc.Agreed on a clear path forward for Vitamin E... MoreAmyris Finalizes Cannabinoid Development, Licensing and Commercialization Agreement Containing $300 Million of R&D and Milestone Payments and a Long-Term Royalty Stream
March 18, 2019 4:20 PM EDTLAVVAN Cites Amyriss Proven Commercial Achievements and Capability to Bring to Market the Highest Quality Cannabinoids for Large Scale Use
EMERYVILLE, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq: AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has signed a final definitive agreement for cannabinoid development, licensing and commercialization containing $300 million of R&D and milestone payments plus long-term royalties. The agreement between Amyris and LAVVAN, Inc., a newly-formed company backed by leaders... More
